Skip to content
Homepage
Author:
Zenas BioPharma
Posted Date:
November 9, 2026
Zenas BioPharma to Present at the Jefferies London Global Healthcare Conference
Zenas BioPharma
November 9, 2026
Zenas BioPharma Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Zenas BioPharma
November 5, 2026
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zenas BioPharma
October 16, 2026
Zenas BioPharma Announces the Presentation of New Obexelimab Data in IgG4-Related Disease at the 6th International Symposium on IgG4-Related Disease
Zenas BioPharma
October 12, 2026
Zenas BioPharma Announces Upcoming Presentations of Orelabrutinib Data in Relapsing Remitting Multiple Sclerosis, Clinical Trial Designs in Progressive Multiple Sclerosis and Other Multiple Sclerosis Portfolio Data at MSToronto2026
Zenas BioPharma
October 7, 2026
Zenas BioPharma to Host Virtual R&D Event
Zenas BioPharma
October 6, 2026
Zenas BioPharma Announces Upcoming Presentations of Obexelimab Data in IgG4-Related Disease at the IgG4ward! 6th International Symposium on IgG4-Related Disease and ACR Convergence 2026
Zenas BioPharma
September 22, 2026
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zenas BioPharma
September 18, 2026
Zenas BioPharma: Obexelimab IgG4-RD Investor Event on Sept 29
Zenas BioPharma
September 8, 2026
Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences
Zenas BioPharma
September 4, 2026
1
2
Next
